All articles tagged with #orforglipron
STAT News explains why turning GLP-1 weight‑loss drugs into pills has been so challenging, highlighting Novo Nordisk’s Wegovy oral version and Lilly’s orforglipron, and what the shift could mean for pricing and accessibility as these pills head toward approval.
In a year-long, head-to-head trial with 1,698 diabetes patients, Eli Lilly’s oral GLP-1 pill orforglipron outperformed Novo Nordisk’s Rybelsus on blood sugar control and weight loss (roughly 15–20 lbs vs 8–11 lbs), with better cardiovascular markers. Higher doses brought more GI side effects (about 10% dropout). The pill can be taken anytime, doesn’t require refrigeration, and Lilly aims for U.S. availability by mid-2026 at about $145–$399 out of pocket.
Eli Lilly CEO Dave Ricks says Medicare coverage of obesity treatments later this year could be a major catalyst for the launch of orforglipron, with a full rollout planned in Q2 and price reductions expected in the second half under Trump-era deals; the move could expand access to 20–30 million beneficiaries and follows strong early demand for competitor Wegovy, a GLP-1 obesity pill.
Six new GLP-1–based obesity drugs are racing to challenge Ozempic/Wegovy, including orforglipron (daily pill) with about 10% weight loss at high dose, CagriSema (semaglutide plus amylin) up to 22.7% in a year, VK2735 (GLP-1 + GIP) up to 12% in 13 weeks, MariTide (monthly injection) up to 20% in a year, Retatrutide (GLP-1 + GIP + glucagon) with nearly 30% weight loss over 68 weeks, and Rejuva (gene therapy to boost GLP-1) in early stages; together signaling a broader, more diverse obesity treatment landscape with FDA actions and safety considerations ahead.
Eli Lilly's oral GLP-1 receptor agonist, orforglipron, successfully maintained weight loss in a Phase 3 trial after patients switched from injectable therapies, leading Lilly to submit it for FDA approval as a treatment for obesity.
Eli Lilly's oral GLP-1 receptor agonist, orforglipron, showed superior glycemic control in two Phase 3 trials, outperforming dapagliflozin and oral semaglutide, with significant A1C reductions and weight loss, supporting its potential as a new standard treatment for type 2 diabetes.
A new oral GLP-1 agonist, orforglipron, has shown promising results in a large trial, helping obese patients lose up to 11% of their body weight over 72 weeks, offering a potentially more accessible alternative to injectable treatments, with significant improvements in cardiometabolic health markers.
Eli Lilly's new oral GLP-1 receptor agonist, orforglipron, demonstrated superior efficacy in reducing A1C levels and weight loss compared to oral semaglutide in a 52-week Phase 3 trial involving adults with type 2 diabetes, with promising safety and tolerability profiles.
Eli Lilly's experimental oral GLP-1 pill, orforglipron, helped overweight adults with type 2 diabetes lose an average of 10.5% of their body weight in a late-stage trial, with significant improvements in blood sugar levels, positioning it as a promising alternative to injectable obesity drugs and potentially paving the way for regulatory approval and market launch next year.
Eli Lilly's oral GLP-1 receptor agonist, orforglipron, successfully met primary and secondary endpoints in a Phase 3 trial, showing significant weight loss and A1C reduction in adults with obesity or overweight and type 2 diabetes, leading to plans for global regulatory submissions.
Eli Lilly's new weight loss pill, orforglipron, successfully cleared its latest trial, showing significant weight loss and blood sugar improvements, paving the way for global approval and offering a potentially more accessible, needle-free alternative to existing treatments for obesity and Type 2 diabetes.
Eli Lilly's new weight loss pill, orforglipron, shows promising trial results with an average weight loss of 12.4% over 72 weeks, nearing the effectiveness of existing injections like Mounjaro and Wegovy. The pill could be easier and cheaper to produce and take, potentially making weight loss treatment more accessible through the NHS, although its efficacy is slightly lower than injectable options. Regulatory approval is anticipated soon, which could mark a significant advancement in obesity management.
Eli Lilly's new pill, orforglipron, has shown promising results in causing significant weight loss in adults with obesity, with an average loss of 27.3 pounds at the highest dose, and the company plans to seek FDA approval by the end of the year. The pill offers a potentially more accessible alternative to injectable weight-loss drugs, with manufacturing advantages, though its full efficacy and safety profile are yet to be fully disclosed.